PCRopsis™ Reagent RVD + PCRopsis™ RVD Enhancer offers a direct PCR solution for specimens in most non-inactivating transport mediums.
PCRopsis™ Reagent RVD alone has been repeatedly shown to facilitate extraction-free amplification of viral, bacterial, and mammalian specimens in universal viral transport (UVT) mediums, like BD™ Universal Viral Transport system. This is one of the most common specimen transport mediums in the U.S., although many other transport mediums are used in the U.S. and abroad.
Entopsis developed PCRopsis™ RVD Enhancer to expand the compatibility of PCRopsis™ Reagent RVD to process specimens in diverse transport mediums. PCRopsis™ Reagent RVD, when used in combination with PCRopsis™ RVD Enhancer, can process specimens in just about any non-inactivating transport medium. Compatible transport mediums now include viral transport mediums recommended by the Centers for Disease Control and World Health Organization, and even a simple phosphate buffered saline (PBS) solution.
“Reagent RVD + RVD Enhancer offers a competitive price and workflow advantage to any laboratory performing PCR-based testing”, said Pratik Sharma, VP of business development at Entopsis.
PCRopsis™ Reagent RVD was recently shown to mediate direct PCR amplification from viral and bacterial targets using low volumes of reagent and sample, thus drastically lowering costs and increasing testing accessibility.
Reagent RVD is a flexible direct PCR product for various research and clinical applications. The PCR testing industry is particularly price-conscious, with thin profit margins. As such, laboratories seek affordable and accurate solutions to offer clients the best services.
Recent miniaturization studies confirm Reagent RVD facilitates extraction-free RT-PCR and qPCR for less than $1.70 per reaction. Typically, RNA and DNA extraction kits cost $4.00 ~ $7.00 per extraction (2~4 times more expensive than Reagent RVD). Moreover, Reagent RVD even offers advantages over alternative direct PCR products currently on the market.
Reagent RVD advantages over alternative direct PCR products:
“It’s interesting how RNA and DNA extraction was mostly taken as a necessary first step in PCR applications for decades. It took the COVID-19 pandemic to get people questioning the validity of that presumption on a large scale. We see the development of affordable and robust direct PCR products as a means of making the PCR diagnostic industry more efficient and equitable”, said Obdulio Piloto, Ph.D., C.E.O. of Entopsis.
“Reagent RVD doesn’t just solve a key problem in the PCR industry, but also offers huge cost savings to partnering labs”, said Pratik Sharma, VP of business development at Entopsis.